Sienna Biopharmaceuticals Reports First Quarter 2019 Financial Results
08. Mai 2019 16:05 ET
|
Sienna Biopharmaceuticals, Inc.
-- Company Completed Positive End-of-Phase 2 Meeting with FDA for SNA-120 in Psoriasis WESTLAKE VILLAGE, Calif., May 08, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA)...
Sienna Biopharmaceuticals Promotes Alexander Azoy to Chief Financial Officer and Appoints Sean Andrews to Leadership Team as Vice President, Investor Relations
21. März 2019 16:05 ET
|
Sienna Biopharmaceuticals, Inc.
-- John W. Smither Departing for Personal Reasons WESTLAKE VILLAGE, Calif., March 21, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA), a clinical-stage biopharmaceutical...
Sienna Biopharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results
14. März 2019 09:05 ET
|
Sienna Biopharmaceuticals, Inc.
WESTLAKE VILLAGE, Calif., March 14, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA), a clinical-stage biopharmaceutical company, today reported the Company’s financial results...
Sienna Biopharmaceuticals to Present at Cowen and Company Health Care Conference
05. März 2019 09:05 ET
|
Sienna Biopharmaceuticals, Inc.
WESTLAKE VILLAGE, Calif., March 05, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA), a clinical-stage biopharmaceutical company, today announced that Frederick C. Beddingfield...
Sienna Biopharmaceuticals Prices Public Offering of Common Stock
20. Februar 2019 08:01 ET
|
Sienna Biopharmaceuticals, Inc.
WESTLAKE VILLAGE, Calif., Feb. 20, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA), a clinical-stage biopharmaceutical company, today announced the pricing of an underwritten...
Sienna Biopharmaceuticals Announces Proposed Public Offering of Common Stock
19. Februar 2019 16:10 ET
|
Sienna Biopharmaceuticals, Inc.
WESTLAKE VILLAGE, Calif., Feb. 19, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA), a clinical-stage biopharmaceutical company, today announced that it has commenced a...
Sienna Biopharmaceuticals’ Novel Silver Photoparticle Technology SNA-001 Successfully Removes Light Hair When Used with Common Laser System
08. Februar 2019 09:05 ET
|
Sienna Biopharmaceuticals, Inc.
-- SNA-001 addresses a large unmet need in laser hair removal by treating light hair using a topical solutionof silver photoparticles, an ultra-efficient light absorber -- -- If cleared, SNA-001 has...
Sienna Biopharmaceuticals® to Present at Dermatology Summit and J.P. Morgan Healthcare Conference
02. Januar 2019 16:30 ET
|
Sienna Biopharmaceuticals, Inc.
WESTLAKE VILLAGE, Calif., Jan. 02, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) today announced that Frederick C. Beddingfield III, M.D., Ph.D., President and Chief...
Sienna Biopharmaceuticals to Present at BMO Capital Markets Healthcare Conference
06. Dezember 2018 16:05 ET
|
Sienna Biopharmaceuticals, Inc.
WESTLAKE VILLAGE, Calif., Dec. 06, 2018 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA), a clinical-stage medical dermatology and aesthetics company, today announced that Frederick...
Sienna Biopharmaceuticals Announces Its Topical, Non-Steroidal TrkA Inhibitor SNA-120 (0.05%) Demonstrated Significant Impact on Psoriasis in Phase 2b Study and Plans to Initiate Phase 3 Psoriasis Trials in Second Half of 2019
03. Dezember 2018 07:05 ET
|
Sienna Biopharmaceuticals, Inc.
-- 27% of subjects achieved 75% reduction in PASI score (PASI 75) vs 13% with vehicle; 29% of subjects achieved two-grade improvement on IGA and ‘clear’ or ‘almost clear’ skin vs 13% with vehicle...